To assess cell-mediated immunity in terms of host protection, an experimental model was developed in which passively transferred spleen cells from immunized AKR/J mice enabled nonimmune syngeneic recipients to survive an otherwise fatal infection with fully virulent Francisella tularensis. Donor immunization was achieved by administering live attenuted tularemia vaccine and, subsequently, the virulent streptomycin-sensitive SCHU S4 strain ofF. tularensis. At selected intervals after immunization, donor spleen cells were transferred to streptomycin-treated recipients challenged subcutaneously, intravenously, or intraperitoneally with 25 to 50 minimal lethal doses of virulent streptomycin-resistant F. tularensis SCHU S5. The protection afforded by immune spleen cells was maximal (essentially 100%) 12 days after the SCHU S4 secondary immunization.
Classical studies by Mackaness and his colleagues (7, 15, (17) (18) (19) (20) with Listeria monocytogenes have provided substantial evidence for cell-mediated immunity as a primary mechanism for acquired resistance against facultative intracellular bacterial infection. Confirmatory experimental data have been reported for the role of cell-mediated immunity in tuberculosis (2, (27) (28) (29) , brucellosis (16) , salmonellosis (3, 6) , and tularemia (1, 4, 14, 30) . However, evidence was based primarily on reduction in growth of the challenge microorganism in the spleen and liver or delay in time to death of laboratory animals that had received dissociated spleen cells and/or macrophages from immune donors (whose serum was found to be inert in passive protection tests).
We postulated that an improved system was required for more precise delineation of specific and nonspecific elements involved in defense against facultative intracellular bacteria and for analysis of the subtle interplay between humoral and cellular factors associated with the expression of immunity. A model using F. tularensis infection in laboratory mice would afford several advantages for such studies: (i) availability of a highly effective live tularemia vaccine prepared from strain LVS (9, 10, 12, 24) and of well-defined, fully virulent streptomycin-sensitive (8, 25) and streptomycin-resistant (22, 26) strains, SCHU S4 and SCHU S5, respectively; and (ii) the marked susceptibility of mice to F. tularensis by various routes of inoculation.
Our goal was to develop a model that would permit syngeneic recipients of immune spleen cells to survive challenge with a fully virulent strain of F. tularensis. In preliminary experiments (unpublished data), when spleen cells were obtained from mice 3, 6, 10, 12, or 19 days post-LVS immunization and were transferred by the intraperitoneal (i.p.) route to syngeneic recipients challenged with strain SCHU S5 by the subcutaneous (s.c.) route, no mice survived challenge. Nonetheless, growth of SCHU S5 in spleens and livers of recipients of 6-day spleen cells was significantly delayed, a finding comparable to that reported by Mackaness (17) Spleen cell suspensions. Spleens were minced with sterile scalpels and pressed through sterile 60-gauge stainless-steel screens (Small Parts Co., Miami, Fla.) into cold RPMI 1640 medium (Grand Island Biological Co., Grand Island, N.Y.) supplemented with 100 U ofpenicillin and 100 ,ug of streptomycin per ml. Cell clumps were dispersed by gentle agitation and passage through a 25-gauge needle. Suspensions were centrifuged at 250 x g for 10 min at 5 C, washed twice with antibiotic-free cold RPMI, and resuspended in the same menstruum. Spleen cell suspensions were used in a ratio of two donor spleens per recipient and cell counts ranged from 1 .0 x 108 to 3.9 x 108; they contained 95 to 99% viable cells when tested by trypan blue (0.5%) exclusion. Differential counts were made by using phase microscopy: mononuclear cells 10 gm or less in diameter were considered to be small lymphocytes and those greater than 10 ,tm, medium to large lymphocytes; lymphoid cells larger than 15 ,im having distinctly indented oval nuclei and vacuolated cytoplasm were counted as macrophages.
Recipients were injected i.p. with 1 ml of spleen cell suspension within 1 h after preparation. At least 1 ml of each suspension was used to estimate the number of spleen cell-associated microorganisms; aliquots of the suspension or dilutions in gelatinsaline were spread on the surface of glucose-cys- Allen (1) ; longer intervals between transfer of cells and challenge were not used to avoid possible development of active immunity. Bactericidal streptomycin treatment (400 jig in 0.1 ml administered s.c. two or three times daily) was initiated immediately after passive transfer of immune spleen cells to eliminate or suppress extracellular growth from cell-associated streptomycin-sensitive LVS or SCHU S4. Normal AKRIJ mice and recipients of normal syngeneic spleen cells were treated in the same manner to ensure the validity of the response to challenge with the streptomycin-resistant SCHU S5 strain. No significant differences in mean time to death were demonstrated between these control groups. In most experiments suspensions of inactivated normal and immune spleen cells were transferred to other control groups; donor cell inactivation was accomplished by heating at 56 C for 30 min or by three cycles of freezing at -60 to -70 C and thawing at 37 C. RESULTS
Resistance of inbred mice to live tularemia vaccine. Immune spleen cell transfer studies were performed initially with strain C57BL/6 mice; however, after vaccination with LVS, 40 to 50% died in contrast to 5% of outbred Swiss CD-1 mice. Consequently, various strains of inbred mice were evaluated for resistance to LVS by various routes of inoculation (Table 1) . Strain AKR/J, although not as resistant as outbred Swiss CD-1 mice, was clearly superior to the other inbred strains evaluated. In addition, AKR/J vaccinees developed a highgrade immunity against SCHU S4 challenge comparable to that of immunized CD-1 mice, i.e., 80 to 100% survival.
Lymphoid population in spleen cell suspensions. Lymphoid cell distribution in suspensions from normal spleens consisted of 65% small lymphocytes, 28% medium to large lymphocytes, 3% neutrophils, and 4% macrophages. In contrast to normal spleens, immune spleens obtained 3 to 19 days after LVS or SCHU S4 booster were two to four times normal weight and their population consisted of 85 to 90% lymphocytes, evenly distributed between small and medium-to-large cells, approximately 4% neutrophils and 9 to 12% macrophages. There were no appreciable morphological differences between cell suspensions from LVS-or SCHU S4-boostered mice. Table 2 , four of six recipients of 6-day post-booster spleen cells survived challenge. This result could be attributed to increased control of cell-associated SCHU S4 by the more intensive (8 h) streptomycin therapy. All recipients that did not receive streptomycin therapy died within 5 days.
In control groups, all mice died within 10 days after challenge; mean time to death varied from 4.3 + 0.5 days to 6.2 + 2.3 days. These challenged control groups included (i) untreated mice, (ii) streptomycin-treated mice, (iii) streptomycin-treated normal spleen cell recipients, (iv) streptomycin-treated recipients of heat-inactivated immune spleen cells, and (v) streptomycin-treated recipients of freezethawed immune spleen cells.
An experiment was conducted to examine the possibility that induction of active immunity by viable intracellular SCHU S4 organisms in the spleen cell transfer could protect recipients in the experimental model, i.e., recipients challenged with SCHU S5 20 h after immune spleen cell transfer. Two normal AKR/J mice were inoculated intravenously (i.v.) with 109 SCHU S4 organisms 3 h before removal of their spleens. A pool of the dissociated spleen cells was suspended for 1 h in cold RPMI 1640 with 100 U of penicillin and 100 ,Ag of streptomycin per ml to eliminate viable extracellular bacteria. The pooled cells were then washed three times in cold RPMI 1640 without antibiotics and diluted to contain approximately 500 or 5,000 viable intracellular SCHU S4 per ml, a concentration comparable to or greater than that recovered from immune spleen cell preparations. Twelve syngeneic recipients were inoculated i.p. with 1 ml of the 500-intracellularorganism preparation and 12 with 1 ml of the 5,000-organism preparation; treatment with streptomycin was initiated immediately and continued at 8-h intervals for a period of 5 days. Six mice from each group were challenged i.p. with 102 SCHU S5 organisms 20 h after transfer and all died within 6 days. Unchallenged recipients of the 5,000-organism preparation also died within this time frame, whereas unchallenged recipients of the 500-organism preparation survived. These findings indicate that in the absence of immune spleen cells, intracellular SCHU S4 organisms were incapable of protecting the recipients.
Effect of challenge route on protective activity of immune spleen cells. Since use of the i.p. route for both cell transfer and challenge might favor the expression ofresistance in recipient mice (1, 13) , the protective activity of immune spleen cells was compared in syngeneic recipients challenged i.v., s.c., or i.p. Immune spleen cells (3.0 x 108) from LVS vaccinees that were boostered on day 30 with SCHU S4 were tranferred i.p. to groups of eight recipient mice 12 days later. Recipients were treated s.c. with streptomycin twice daily for 5 days. All mice including normal spleen cell recipients and chalenge controls were inoculated with 26 MLD of strain SCHU S5 20 h after spleen cell transfer. Survival ratios (Table 4) indicated that the route of challenge had no significant effect on expression of protective activity conferred by immune spleen cells. DISCUSSION Our data demonstrate that under appropriate conditions passively transferred spleen cells from mice immunized with live tularemia vaccine will ensure high-grade protection (survival approaching 100%) to nonimmune recipients against i.v., i.p., or s. c. challenge with a fully virulent strain ofF. tularensis. The experimental model consists of: (i) primary immunization of 11-to 14-week AKRNJ mice with live tularemia vaccine; (ii) secondary immunization on day 30 with virulent strain SCHU S4; (iii) 12 days after booster, immune spleen cell transfer to syngeneic recipients challenged 20 h later by the i.p., s.c., or i.v. route with 25 to 50 MLD of streptomycin-resistant strain SCHU S5; and (iv) administration of streptomycin therapy to all recipient mice for 5 days from time of spleen cell transfer.
Early reports on the influence of the genetic constitution of the host (11, 31) established that inbred strains of mice differed in their resistance to various bacterial or viral agents. More recently (23) marked differences were noted between A/J and C57BL/6J mice in their resistance to the facultative intracellular bacteria Salmonella typhimurium and L. monocytogenes; the A/J strain was strikingly resistant to S. typhimurium but highly susceptible to L. monocytogenes, whereas the reverse was shown for the C57BL/6J strain. We have demon- strated that inbred mouse strains differ appreciably in resistance to live tularemia vaccine and that of eight strains evaluated the AKR/J proved most satisfactory for investigation of cell-mediated immunity in tularemia.
Effective induction of immune spleen cells by 103 SCHU S4 but not by 106 LVS organisms cannot be readily explained by qualitative and quantitative differences in post-booster spleen cell populations. Postulates based upon antigenic differences between the strains were weakened by the knowledge that vaccination with strain LVS affords high-grade immunity to the AKRNJ mouse and other hosts against challenge with strain SCHU S4. Since cell-associated viable LVS organisms were never cultured from suspensions of spleen cells from LVS-boostered mice, it is possible that a lack of sufficient antigenic stimulus to immunologically committed T-cells might not provide macrophage activation at a level sufficiently high to result in expression of immunity (21) . This hypothesis is currently under investigation.
Data presented in Tables 2 and 3 reveal that survival of challenged mice is appreciably influenced by the time interval at which the immune spleen cells are transferred after booster. The effect on survival as influenced by the number of spleen cell-associated SCHU S4 transferred and/or the frequency of streptomycin treatment cannot be definitively determined from the available data. However, differences between the degree of protection of 6-day immune spleen cell recipients noted in Table 2 (no survival) and Table 3 (67% survival) could have been due to the increased effectiveness of 8 h rather than 12 h of streptomycin treatment in limiting replication of SCHU S4 organisms. Mackaness (15, 17) reported that lymphoid cells from Listeria-infected mice were significantly less effective for transfer of immunity if harvested within 1 to 4 days; his data indicated that a considerable number of viable organisms were present in 4-day spleen cell suspensions. In a comprehensive study on possible explanations for this discrepancy are: (i) the strains and/or method for immunization of donor mice provided a more effective spleen cell population; or (ii) the AKRIJ mouse was more immunocompetent for F. tularensis than the inbred strain used by Allen (1) .
Inherent to any system that incorporates transfer of immune cells and cell-associated replicating microorganisms is the possibility that active immunity may be induced in immune cell recipients. This is a particularly difficult problem when survival is the parameter used to evaluate cell-mediated immunity. Our data clearly indicate that at the time of challenge (20 h after spleen cell transfers) nonimmune spleen cells containing F. tularensis were incapable of preventing fatal infection with SCHU S5, whereas immune spleen cells containing a comparable number of organisms afforded complete protection. Indeed, significant protection was afforded by transfer of immune spleen cells containing as many as 104 viable SCHU S4. In marked contrast, recipients of normal spleen cells containing 5 x 103 SCHU S4 died within 6 days despite streptomycin therapy. Although these data imply that active immunity is not a significant factor in the survival of immune cell recipients, they do not eliminate it as a contributing factor. A definitive model would require absence of replicating organisms in transferred immunocompetent cells, and investigations toward this end are currently in progress.
